Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286

Allan R Tenorio; Ellen S Chan; Ronald J Bosch; Bernard J C Macatangay; Sarah W Read; Suria Yesmin; Babafemi Taiwo; David M Margolis; Jeffrey M Jacobson; Alan L Landay; Cara C Wilson; A5286 Team

doi:10.1093/infdis/jiu515

Back

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286

Journal article

Open access

Peer reviewed

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286

Allan R Tenorio, Ellen S Chan, Ronald J Bosch, Bernard J C Macatangay, Sarah W Read, Suria Yesmin, Babafemi Taiwo, David M Margolis, Jeffrey M Jacobson, Alan L Landay, …

The Journal of infectious diseases, v 211(5), pp 780-790

01 Mar 2015

DOI: https://doi.org/10.1093/infdis/jiu515

PMID: 25214516

Featured in Collection : UN Sustainable Development Goals @ Drexel

Files and links (2)

url

https://academic.oup.com/jid/article-pdf/211/5/780/16867097/jiu515.pdfView

Published, Version of Record (VoR) Open

url

https://doi.org/10.1093/infdis/jiu515View

Published, Version of Record (VoR) Open

Abstract

Adolescent

Adult

Aged

Anti-Bacterial Agents - therapeutic use

Antiretroviral Therapy, Highly Active - methods

Bacterial Translocation

CD8-Positive T-Lymphocytes - immunology

Female

HIV Infections - complications

HIV Infections - drug therapy

Humans

Inflammation - prevention & control

Lipopolysaccharide Receptors - blood

Lipopolysaccharides - blood

Lymphocyte Activation

Male

Middle Aged

Rifamycins - therapeutic use

Treatment Outcome

Young Adult

Rifaximin, a nonabsorbable antibiotic that decreases lipopolysaccharide (LPS) in cirrhotics, may decrease the elevated levels of microbial translocation, T-cell activation and inflammation in human immunodeficiency virus (HIV)-positive immune nonresponders to antiretroviral therapy (ART). HIV-positive adults receiving ART for ≥96 weeks with undetectable viremia for ≥48 weeks and CD4(+) T-cell counts <350 cells/mm(3) were randomized 2:1 to rifaximin versus no study treatment for 4 weeks. T-cell activation, LPS, and soluble CD14 were measured at baseline and at weeks 2, 4, and 8. Wilcoxon rank sum tests compared changes between arms. Compared with no study treatment (n = 22), rifaximin (n = 43) use was associated with a significant difference between study arms in the change from baseline to week 4 for CD8(+)T-cell activation (median change, 0.0% with rifaximin vs +0.6% with no treatment; P = .03). This difference was driven by an increase in the no-study-treatment arm because there was no significant change within the rifaximin arm. Similarly, although there were significant differences between study arms in change from baseline to week 2 for LPS and soluble CD14, there were no significant changes within the rifaximin arm. In immune nonresponders to ART, rifaximin minimally affected microbial translocation and CD8(+)T-cell activation. Trial registration number. NCT01466595.

Metrics

5 Record Views

65 citations in Web of Science

65 citations in Scopus

Details

Title: Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286
Creators: Allan R Tenorio - Department of Medicine
Ellen S Chan - Harvard University
Ronald J Bosch - Harvard University
Bernard J C Macatangay - University of Pittsburgh
Sarah W Read - National Institutes of Health
Suria Yesmin - Social and Scientific Systems (United States)
Babafemi Taiwo - Northwestern University
David M Margolis - University of North Carolina at Chapel Hill
Jeffrey M Jacobson - Drexel University
Alan L Landay - Rush University
Cara C Wilson - University of Denver
A5286 Team
Publication Details: The Journal of infectious diseases, v 211(5), pp 780-790
Publisher: Oxford University Press
Grant note: UM1 AI069447 / NIAID NIH HHS U01 AI069534 / NIAID NIH HHS AI069470 / NIAID NIH HHS UM1 AI069556 / NIAID NIH HHS U01 AI069452 / NIAID NIH HHS AI069419 / NIAID NIH HHS AI069432 / NIAID NIH HHS U01 AI069471 / NIAID NIH HHS AI069481 / NIAID NIH HHS UM1 AI069471 / NIAID NIH HHS UM1 AI069503 / NIAID NIH HHS AI069424 / NIAID NIH HHS AI069503 / NIAID NIH HHS AI069477 / NIAID NIH HHS TR001070 / NCATS NIH HHS UM1 AI069534 / NIAID NIH HHS U01 AI069447 / NIAID NIH HHS U01 AI069556 / NIAID NIH HHS AI50410 / NIAID NIH HHS U01 AI069494 / NIAID NIH HHS UM1 AI069452 / NIAID NIH HHS U01 AI069439 / NIAID NIH HHS UM1 AI069439 / NIAID NIH HHS AI069447 / NIAID NIH HHS AI069532 / NIAID NIH HHS UM1 AI069494 / NIAID NIH HHS U01 AI069432 / NIAID NIH HHS AI069415 / NIAID NIH HHS AI073961 / NIAID NIH HHS U01 AI068636 / NIAID NIH HHS UL1 TR000457 / NCATS NIH HHS AI069412 / NIAID NIH HHS UL1 TR001111 / NCATS NIH HHS P30 AI045008 / NIAID NIH HHS U01 AI069511 / NIAID NIH HHS P30 AI050410 / NIAID NIH HHS A1025439 / PHS HHS U01 AI069477 / NIAID NIH HHS AL050404 / PHS HHS U01 AI069501 / NIAID NIH HHS RR024160 / NCRR NIH HHS UM1 AI069424 / NIAID NIH HHS TR001111 / NCATS NIH HHS UM1 AI068634 / NIAID NIH HHS U01 AI069419 / NIAID NIH HHS AI069501 / NIAID NIH HHS U01 AI069502 / NIAID NIH HHS UM1 AI069532 / NIAID NIH HHS U01 AI069412 / NIAID NIH HHS AI069494 / NIAID NIH HHS UM1 AI069423 / NIAID NIH HHS UM1 AI069415 / NIAID NIH HHS UL1 RR024160 / NCRR NIH HHS U01 AI069423 / NIAID NIH HHS U01 AI069532 / NIAID NIH HHS AI068636 / NIAID NIH HHS UM1 AI068636 / NIAID NIH HHS U01 AI069481 / NIAID NIH HHS P30 AI073961 / NIAID NIH HHS UL1 TR001070 / NCATS NIH HHS UM1 AI069418 / NIAID NIH HHS U01 AI069415 / NIAID NIH HHS AI069418 / NIAID NIH HHS UM1 AI069502 / NIAID NIH HHS U01 AI069470 / NIAID NIH HHS UM1 AI069412 / NIAID NIH HHS UM1 AI069481 / NIAID NIH HHS AI069471 / NIAID NIH HHS UM1 AI106701 / NIAID NIH HHS UM1 AI069501 / NIAID NIH HHS AI069511-08 / NIAID NIH HHS AI069423 / NIAID NIH HHS UM1 AI069470 / NIAID NIH HHS AI069556 / NIAID NIH HHS AI069502 / NIAID NIH HHS AI069452 / NIAID NIH HHS U01 AI069503 / NIAID NIH HHS U01 AI069418 / NIAID NIH HHS AI069439 / NIAID NIH HHS UL1 TR000042 / NCATS NIH HHS UL1 TR001082 / NCATS NIH HHS UM1 AI069511 / NIAID NIH HHS UM1 AI069477 / NIAID NIH HHS UL1 TR000439 / NCATS NIH HHS AI045008 / NIAID NIH HHS AI069534 / NIAID NIH HHS TR000439 / NCATS NIH HHS UM1 AI069432 / NIAID NIH HHS TR001082 / NCATS NIH HHS U01 AI069424 / NIAID NIH HHS UM1 AI069419 / NIAID NIH HHS U01 AI068634 / NIAID NIH HHS
Resource Type: Journal article
Language: English
Web of Science ID: WOS:000350222000013
Scopus ID: 2-s2.0-84939509426
Other Identifier: 991019335327604721

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration
Web of Science research areas: Immunology; Infectious Diseases; Microbiology

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286

Files and links (2)

Abstract

Metrics

Details

UN Sustainable Development Goals (SDGs)

InCites Highlights

Drexel University Social media